All audiences
For Biotech
De-risk indication expansion for clinical-stage biotech.
Validate repositioning hypotheses before committing scarce clinical resources. Our five-tier evidence grading separates approved indications from speculative claims.
Platform capabilities
- Mechanism-aligned target mapping
- ClinicalTrials.gov integration
- Phase-appropriate evidence tiers
- Scientific → medical review workflow
- Insufficient evidence flagging
Repositioning Intelligence is a research and decision-support tool for qualified professionals. It does not provide medical advice, diagnosis, or treatment recommendations. Contact your organization's medical affairs team for clinical decisions.